RecruitingNCT05117125

Biomarkers for Ventilator-associated Pneumonia

Biomarkers for Prediction of and Diagnosis of Ventilator-associated Pneumonia

Sponsor

Region Skane

Enrollment

1,000 participants

Start Date

Oct 15, 2021

Study Type

OBSERVATIONAL

Conditions

Pneumonia, Ventilator-Associated

Summary

The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Bacterial transcriptome, Heparin-binding protein, and others for people with pneumonia, ventilator-associated. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTHeparin-binding protein

Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.

DIAGNOSTIC_TESTInterleukin-26

Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.

DIAGNOSTIC_TESTMicrobiome

Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.

DIAGNOSTIC_TESTBacterial transcriptome

Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.

DIAGNOSTIC_TESTProteome

Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.

Locations(5)

Vestre Viken

Drammen, Norway

Hospital de São Francisco Xavier

Lisbon, Portugal

Skåne University Hospital, Dept. of Infectious diseases

Lund, Sweden

Skåne university Hospital, ICU

Malmö, Sweden

Karolinska University Hospital, ICU

Solna, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05117125

Related Trials

Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients

NCT058437869 locations

VAP Incidence and Adequation to SRLF 2017 Diagnostic Among an Intensive Care Medicine Service for the Period 2022 à 2024

NCT071818241 location

Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)

NCT0724003839 locations

Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients

NCT070526041 location

Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response

NCT064678641 location